2021
DOI: 10.1620/tjem.255.49
|View full text |Cite
|
Sign up to set email alerts
|

Enzymatic Changes in Red Blood Cells of Diamond-Blackfan Anemia

Abstract: Diamond-Blackfan anemia is a congenital bone marrow failure syndrome characterized by red blood cell (RBC) aplasia with varied malformations in infants. Elevated activity of adenosine deaminase (ADA) has been considered as a useful biomarker of Diamond-Blackfan anemia, and ADA assay has been shown to be more sensitive than genetic diagnosis. Approximately, 80% of the examined patients showed elevated ADA activity, whereas genetic tests of ribosome subunit genes identified mutations in approximately 60% of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 28 publications
0
1
0
Order By: Relevance
“…ADA1 deficiency-induced SCID can be treated by enzyme replacement therapy (ERT) with polyethylene-glycol-modified ADA (PEG-ADA) or gene therapy ( 3 ). Moreover, elevated ADA1 activity in erythrocytes has been considered the biomarker of Diamond-Blackfan anemia ( 4 ).…”
Section: Introductionmentioning
confidence: 99%
“…ADA1 deficiency-induced SCID can be treated by enzyme replacement therapy (ERT) with polyethylene-glycol-modified ADA (PEG-ADA) or gene therapy ( 3 ). Moreover, elevated ADA1 activity in erythrocytes has been considered the biomarker of Diamond-Blackfan anemia ( 4 ).…”
Section: Introductionmentioning
confidence: 99%